APM vs. ORGS, NRBO, NRSN, FLGC, GLTO, INDP, VINC, NERV, BIVI, and KALA
Should you be buying Aptorum Group stock or one of its competitors? The main competitors of Aptorum Group include Orgenesis (ORGS), NeuroBo Pharmaceuticals (NRBO), NeuroSense Therapeutics (NRSN), Flora Growth (FLGC), Galecto (GLTO), Indaptus Therapeutics (INDP), Vincerx Pharma (VINC), Minerva Neurosciences (NERV), BioVie (BIVI), and KALA BIO (KALA). These companies are all part of the "pharmaceutical preparations" industry.
Aptorum Group (NASDAQ:APM) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings.
Aptorum Group has higher earnings, but lower revenue than Orgenesis.
In the previous week, Aptorum Group had 1 more articles in the media than Orgenesis. MarketBeat recorded 3 mentions for Aptorum Group and 2 mentions for Orgenesis. Orgenesis' average media sentiment score of 1.43 beat Aptorum Group's score of 1.19 indicating that Orgenesis is being referred to more favorably in the news media.
Aptorum Group has a net margin of 0.00% compared to Orgenesis' net margin of -1,010.50%. Aptorum Group's return on equity of 0.00% beat Orgenesis' return on equity.
Aptorum Group received 40 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 68.33% of users gave Aptorum Group an outperform vote.
Aptorum Group has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 64.0% of Aptorum Group shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Aptorum Group beats Orgenesis on 8 of the 13 factors compared between the two stocks.
Get Aptorum Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptorum Group Competitors List
Related Companies and Tools
